FDA clears Excel Medical predictive algorithm for patient monitoring

Excel Medical has received FDA clearance for WAVE Clinical Platform, a remote patient monitoring and predictive algorithm.

The WAVE includes a remote monitoring platform capable of producing real-time clinical data such as waveforms and alarms for at-risk patients through hospital workstations, mobile devices and electronic health records. Additionally, the predictive algorithm can determine patient risk to help prevent deterioration up to six hours before conventional methods. In testing the algorithms accuracy, researchers found it was able to improve prediction of death in all six of the patients within the control group.

“Everything we do as an organization aligns toward and supports the goal of eradicating unexpected deaths in hospitals. People may say zero unexpected deaths is unattainable. We say anything other than zero is unconscionable,” said Lance Burton, general manager with Excel Medical. “We look forward to bringing other revolutionary predictive algorithms to the WAVE platform soon, many of which are currently under development.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.